About: Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
Creator	Chan, Jasper Fuk-Woo Tse, Herman Yuen, Kwok-Yung Wang, Ming Chan, Kwok-Hung Lau, Susanna Kar-Pui Chiu-Yat Woo, Patrick Chen, Honglin Cai, Jian-Piao Lau, Candy Choi-Yi Xiao, Xincai Zheng, Bo-Jiang To, Kai-Wang Tsang, Ka-Lun
Source	Elsevier; Medline; PMC
abstract	Summary Objectives A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to Tylonycteris-bat-coronavirus-HKU4 and Pipistrellus-bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans. Methods Anti-HCoV-EMC and anti-SARS-CoV antibodies were detected using screening indirect immunofluorescence (IF) and confirmatory neutralizing antibody tests. Results Two (2.1%) animal handlers had IF antibody titer of ≥1:20 against both HCoV-EMC and SARS-CoV with neutralizing antibody titer of <1:10. No blood donor had antibody against either virus. Surprisingly, 17/28 (60.7%) of SARS patients had significant IF antibody titers with 7/28 (25%) having anti-HCoV-EMC neutralizing antibodies at low titers which significantly correlated with that of HCoV-OC43. Bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of Spike protein. Virulence of SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing antibodies against other betacoronaviruses. Conclusions Convalescent SARS sera may contain cross-reactive antibodies against other betacoronaviruses and confound seroprevalence study for HCoV-EMC.
has issue date	2013-08-31(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2013.03.015
bibo:pmid	23583636
has license	els-covid
sha1sum (hex)	1a43a0980cd9d8025ff37de176287af5cd9fa0ff
schema:url	https://doi.org/10.1016/j.jinf.2013.03.015
resource representing a document's title	Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
has PubMed Central identifier	PMC7112694
has PubMed identifier	23583636
schema:publication	Journal of Infection
resource representing a document's body	covid:1a43a0980cd9d8025ff37de176287af5cd9fa0ff#body_text
is schema:about of	named entity 'seroprevalence' named entity 'PATIENTS' covid:arg/1a43a0980cd9d8025ff37de176287af5cd9fa0ff named entity 'NOVEL' named entity 'GAME' named entity 'EMC' named entity 'LIKE' named entity 'PIPISTRELLUS' named entity '152' named entity 'SARS' named entity 'NOVEL' named entity 'DISEASE' named entity 'RELATED' named entity 'WILD' named entity 'TYLONYCTERIS' named entity 'PATIENTS' named entity 'BLOOD' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'OBJECTIVES' named entity 'HUMAN CORONAVIRUS' named entity 'ANTIBODY TESTS' named entity 'DUE TO' named entity 'EMC' named entity 'ANTIBODIES' named entity 'CROSS-REACTIVE' named entity 'SARS' named entity 'IMMUNOFLUORESCENT' named entity 'NEUTRALIZING ANTIBODY' named entity 'CONVALESCENT' named entity 'STUDY' named entity 'SERA' named entity 'SEROPREVALENCE' named entity 'ARCHIVED' named entity 'CORONAVIRUS' named entity 'HUMAN CORONAVIRUS' named entity 'AUTHOR' named entity 'SERA' named entity 'MARKET' named entity 'BAT' named entity 'LIFE' named entity 'BETACORONAVIRUS' named entity 'HONG KONG' named entity 'HEALTHY' named entity 'FOOD ANIMAL' named entity 'RECENTLY' named entity 'emerged' named entity 'disease' named entity 'patients' named entity 'Hong Kong' named entity 'SARS' named entity 'coronavirus' named entity 'bat' named entity 'human coronavirus' named entity 'Cross-reactive' named entity 'United Kingdom' named entity 'SARS-CoV' named entity 'HCoV-EMC' named entity 'heptad repeat' named entity 'SARS' named entity 'fluorescent' named entity 'immunogenic' named entity 'Southern China' named entity 'antibody titer' named entity 'serum' named entity 'Institutional Review Board' named entity '1:160' named entity 'microscopy' named entity 'HCoV-EMC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software